Fibrocell in deal with Intrexon

Fibrocell Science Inc. (OTCBB:FCSC) announced a deal to use synthetic biology technologies from Intrexon Corp. (Blacksburg, Va.) to develop and commercialize next-generation autologous fibroblast and dermal cell therapies. The deal includes access to Intrexon's UltraVector technology and its platforms for genome, protein and cell processing engineering. Intrexon will receive an upfront payment that consists of $3.3 million in Fibrocell stock at a price of $0.10 per share. Intrexon is also eligible for royalties. ...